pre-IPO PHARMA

COMPANY OVERVIEW

Amphivena's mission is to eradicate blood cancers with a breakthrough therapy that harnesses the patient’s own immune system to destroy tumor cells and their precursors. Their aim is to restore the cellular balance needed for proper blood formation, function and circulation, restoring the flow of life to patients.


LOCATION

  • South San Francisco, CA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://amphivena.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    mpm-capital


    PRESS RELEASES


    Jun 4, 2021

    Amphivena Presents New Monotherapy and First Combination Therapy Clinical Data in Solid Tumor Patients


    Apr 12, 2021

    Amphivena Presents Translational Data Highlighting the Cytokine Profile for its Lead Clinical Candidate, AMV564 at the AACR 2021 Virtual Annual Meeting


    Dec 16, 2020

    Amphivena Therapeutics Announces First Patient Dosed in the Phase 1 Dose Expansion of AMV564


    Dec 9, 2019

    Amphivena Reports Data on Phase 1 Study of AMV564 at Ash Annual Meeting


    Dec 2, 2019

    Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer


    For More Press Releases


    Google Analytics Alternative